of Standards and Technology (NIST, Gaithersburg, MD) as an accuracy material for nine of the analytesto be studied because the values assigned by NIST are based on analyses by individual NIST-developed Definitive
Methods [J_9]3
The unique featureof SRM 909a forlong-term comparabilitypurposes is that values for successive lots are assignedon the basis of actual Definitive Method measurement data rather than on the long-term stability of a single material. We used SR.M 909a to assessthe ongoing accuracyof results obtained with six multianalyteinstruments during the 3 years 1991-1993. During this period, we identified as defectivethree vials of SRM 909a, in which the glucose recoveredwas lessthan 30% of the assigned NIST value. Other vials from the same shipments yielded 95-104% recovery for glucose measured on the same day with the same instruments, reagents,calibrators, and dailyquality-control materialsand procedures [10] .
Here, we report the analyterecovery studiesfor the three defective vials (two 909a-l, and one 909a-2) and for three concurrent acceptable vials and summarize the results of eight studies to determine the cause of the problem. and creatininereagent was from Sclavo (Wayne, NJ). BMC reagents were used for all analytes on the Hitachi 747 and 717 instruments. Beckman reagents were used for all CX3 determinations. STANDARD 
REFERENCE MATERIALS
Two separateshipments of SRM 909a were received in dry ice (1 box/shipment) from NIST: the first in March 1992 and the second in October 1992. The boxes were stored at 4 #{176}C. The vials forwhich results are reported here were used within 1 year from the date of shipment, as specified in the package insert.
A box of SRM 909a consists of sixvials, three bottles each of two concentrationsof analyte (909a-1 and 909a-2) in freezedried serum. All vialswere reconstituted according to direction method B in the product insert descriptive data for SRM 909a. After reconstitution, the analytes were assayed within 1-2 h. The NIST-recommended period is to assay within 8 h after reconstitution.
ANALYSIS PROTOCOL
All vials were analyzed in the same manner as patients' samples and in triplicate for all analytes. When a defective vial was identified, we reconstituted a second vial of the same 909a lot and concentration and analyzed it that same day within 2 h, using the same instruments, the same reagents, the same calibrators, and the same daily quality-control acceptance criteria. We also analyzed one vial of the other concentration from that lot. 12] ; creatinine was measured by a modified Jaffe reaction involving kinetic measurements to reduce interference by noncreatinine substances [13, 14] ; electrolytes were measured by indirect potentiometry [15, 16] ; glucose was measured by the reduction of NAD + in a coupled reaction between hexokinase and glyceraldehyde-3-phosphate dehydrogenase [17] ; urea nitrogen was measured by a complex enzyme assay in which the rate of oxidation of NADH to NAD is monitored spectrophotometrically [18] ; and uric acid was measured by uncase and catalase enzymes with production of a quinoneoxime dye complex, the color of which was measured bichnomatically [19] .
Analysis by
Analysis by Beckman CX3 analyzers. Glucose was measured by oxygen consumption (amperometry) with use of glucose oxidase [20] ; monovalent ions were measured by indirect potentiometry [21] [22] [23] ; creatinine was measured by a modified Jaffe reaction [13, 14] ; and urea nitrogen was measured by the increasein conductivity after addition of urease [24] .
INVESTIGATIVE METHODOLOGY
The eight methods used to investigate the causes of the defective vials were: pH (Ciba-Corning Diagnostics method), lactic acid [25, 26] , bacterial Gram stain [27] , bacterial culture [28] , sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) [29] , ultracentrifugation [30] , total protein [31, 32] , and electron microscopy [33] . Analytically accepted procedures were used throughout.
A detailed description of the investigative methodology is provided in an Appendix, which is available from the corresponding author upon request. In the course of these studies, between August 1992 and February 1993, we encountered three defective vials of SRM 909a. Table 1 shows the glucoserecovery as a percent of the labeledNIST SRM 909a value for each defective vialand for its concomitant acceptablevial. Table 2 shows the complete analytical recovery data for a The ranges assigned by the NIST and the stated uncertainties, defined as 95%/95% statistical tolerance intervals, which reflect the combined effects of measurement imprecision and the variability of the mass of dry serum among vials. Thus, 95% of the reconstituted vials would have analyte values falling within these specified ranges.
Results

NIST
Average of three measurements each.
Percent ofrecovery is listed in parentheses.
d Aberrant methodolo,.
ND, not done due to lack of method channel.
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De et al.: Defectivevialsof NIST SRM 909a analyzers. As Table 3 shows, the sentinel analyte value for a defective vial was a glucose recovery of <30%. 
INVESTIGATION OF CAUSES FOR DEFECTIVE RECOVERY OF
GLUCOSE
Eight aspectsof the defectivevialmaterialwere examined to identify an assignable cause for the defective glucose recovery. Acceptable vials were subjected to the same studies. Table 4  compares the results of seven of the eight investigational procedures for two pairs of defective and acceptable vials (11/4/92 and 2/10/93); the eighth comparison, protein electrophoresis, is shown in Fig. 1 .
The pH of the defective material was 0.6 pH unit lower than in the acceptable vials. The lactic acid content in defective vials was 86% greater than the baseline values of the acceptable vials.
There was no difference in the quantitative total protein concentration in the defective and the acceptable vials. After ultracentrifugation, we measured the total protein in the pellet and the supematant independently.
The insoluble pellet protein concentration had increased by 2.4 times in the defective vial 909a-1 (2/10/93) and by 3.1 times in the defective vial 909a-2 (11/4/93) compared with the similarly prepared insoluble pellet protein from the corresponding acceptable vials. The visual turbidity of the reconstituted material correlated with the increase in the insoluble pellet protein.
Total protein recovery was between 99% and 102% of the preultracentrifuged value.This indicates that the differencein insoluble protein between the defective and the acceptable vials is realand not a recovery artifact from the separationof the solubleand insolublefractions.
The precision(SD) of total proteinmeasurement at 50 g/L is 1.2 g/L by the Hitachi biuret method [31] . Therefore, we conclude that there was no significant difference in total protein between acceptable and defective vials. Because the pellet protein concentrations were very low, we confirmed these protein values by the more precise method of Lowry et al. [32] .
To (Fig. 1) . All bands were consistently present in all fractions in both defective and acceptable vials, and no new bands were visible in the lanes of sample from defective vial 909a-2.
B
In addition,Gram stainsof the reconstituted defective and acceptablevial materials were negative for stainable bacteria [27] 10 11 12 ( Table 4) . Use of a sensitive bacterial growth method, i.e., broth culture at 37 #{176}C, revealed no identifiable microorganisms in either defective or acceptable vials [28] .
Finally, electron microscopic sections of the insoluble pellet materials obtained from ultracentrifugation of samples from defective and acceptable vials of 909a at both concentrations, showed no evidence of intact bacterial organisms, bacterial membranes, or bacterial fragments or cellular components (Fig. 2) .
Discussion
Comparison of the results for three defective vials gives convincing evidence of discrepancies between the glucose, cholesterol, and uric acid concentrations in SRM 909a-l/a-2 and their listed target values. The most affected analyte was glucose, followed by uric acid and cholesterol, in all three defective vials; other analytes in the defective vials were unaffected.
When evidence is presented indicating a flaw in an important national standard, specific precautions must be taken to rule out the possibility that the observation could be a defect in the measurement system. Hence, we report the specific precautions we took:
1. Multiple instruments were used in the same way, which ruled out the possibility of idiosyncratic performance by a single instrument.
2. Both defective and acceptable vials were analyzed on the same day, within the 8-h NEST-recommended postreconstitution time limit. This ruled out the possibility of a time-related sporadic change in instrument, reagent, calibrator, or NEST sample.
3. Analysis of acceptable vials from the same box that contained a defective vial ruled out a localized phenomenon that would affect all vials in a specific box, e.g., unfavorable shipping or storage conditions. 4. The occurrence of defective vials in different shipments over a 6-month period pointed toward a prestorage event rather than a localized storage depot problem.
5.
In addition, because the triplicate analyses used throughout the study checked within a range of 2% or less, the consistent level of precision ruled out the possibility that the observed changes in the defective vials were attributable to poor instrument precision.
6. Between the two CX3 instruments, the widest analyte recovery range was 6% (94-100% for urea nitrogen 
